← SynDRA
ADAGRASIB
SynDRA canonical compound SYN0040002 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
| Approval status | Approved · Rx/OTC |
| Primary target(s) | KRAS |
| Mechanism of action | ras gtpase inhibitor |
| Indication | gastric adenocarcinoma |
| Disease area | oncology |
All known targets
Mechanisms of action (all sources)
- KRAS INHIBITOR
- GTPase KRas inhibitor
- ras gtpase inhibitor
Drug classes
ATC classes
- L01X · OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- krazati
- MRTX849
- KRAS G12C INHIBITOR MRTX849
- KRAZATI
- MRTX-849
- ADAGRASIB (MRTX849)
- COMPOUND 20
- MRTX 849
- UNII-8EOO6HQF8Y
- 8EOO6HQF8Y
- 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile
- CHEMBL4594350
- SCHEMBL20974691
- GTPL10888
- Kras G12C inhibitor MRTX849
- BCP31538
- EX-A3258
- MFCD32263433
- s8884
- compound 20 [PMID: 32250617]
- BS-16211
- HY-130149
- CS-0105265
- 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)-
- RefChem:56312
- DTXCID001767019
- Adagrasib [USAN]
- Adagrasib (MRTX849)
- Krazati (TN)
- ADAGRASIB [INN]
- Adagrasib (USAN/INN)
- MRTX849(Adagrasib)?
- ADAGRASIB [WHO-DD]
- C32H35ClFN7O2
- orb1298993
- SCHEMBL29349856
- SCHEMBL29423703
- SCHEMBL29979738
Look up ADAGRASIB in the interactive SynDRA portal →